PMID- 34231442
OWN - NLM
STAT- MEDLINE
DCOM- 20211014
LR  - 20211014
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 14
IP  - 10
DP  - 2021 Oct
TI  - Patient initiation and maintenance of GLP-1 RAs for treatment of obesity.
PG  - 1193-1204
LID - 10.1080/17512433.2021.1947796 [doi]
AB  - Introduction: Healthcare providers (HCPs) see many patients with obesity-related 
      complications and are therefore well placed to help treat obesity itself. 
      However, limited collated information exists to help HCPs with the practical use 
      of anti-obesity medications (AOMs). We focus on the initiation and maintenance of 
      a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for weight management, 
      liraglutide 3.0 mg. Literature search was conducted between 25-28 November 2019 
      on PubMed and ClinicalTrials.gov.Areas covered: Clinical trial and real-world 
      data describing weight-loss efficacy, cardiometabolic risk factors, incidence of 
      adverse events (AEs), and persistence are presented to assist HCPs with patient 
      discussions. Practical considerations to overcome barriers to optimal use are 
      provided, equipping HCPs with the information required to aid with adherence to 
      and persistence with AOMs. The use of other GLP-1- RA therapies in obesity is 
      discussed in light of the recent US Food and Drug Administration approval of 
      semaglutide 2.4 mg for weight management.Expert opinion: Liraglutide 3.0 mg 
      provides benefits regarding weight loss and improvements in cardiometabolic risk 
      factors. Promising areas of future research in the field of obesity include dual 
      receptor agonists and the combination of glucagon-like peptide-1 receptor 
      agonists with other molecules.
FAU - Patel, Dhiren
AU  - Patel D
AD  - School of Pharmacy, Pharmacy Practice, MCPHS University, Jamaica Plain, Boston, 
      MA, USA.
AD  - Endocrine Department, VA Boston Healthcare System, Boston, MA, USA.
FAU - Smith, April
AU  - Smith A
AD  - School of Pharamacy and Health Professions, Creighton University, Omaha, NE, USA.
AD  - Weight Management Bariatric Center, CHI Immanuel Medical Center, Bariatric & 
      General Surgery, Omaha, NE, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210707
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 53AXN4NNHX (semaglutide)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Animals
MH  - Anti-Obesity Agents/adverse effects/*pharmacology
MH  - Cardiometabolic Risk Factors
MH  - Glucagon-Like Peptide-1 Receptor/*agonists/metabolism
MH  - Glucagon-Like Peptides/adverse effects/pharmacology
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/pharmacology
MH  - Liraglutide/adverse effects/pharmacology
MH  - Obesity/*drug therapy/physiopathology
MH  - Weight Loss/drug effects
OTO - NOTNLM
OT  - Anti-obesity medication
OT  - GLP-1 RA
OT  - liraglutide 3.0 mg
OT  - obesity
OT  - weight management
EDAT- 2021/07/08 06:00
MHDA- 2021/10/15 06:00
CRDT- 2021/07/07 08:43
PHST- 2021/07/08 06:00 [pubmed]
PHST- 2021/10/15 06:00 [medline]
PHST- 2021/07/07 08:43 [entrez]
AID - 10.1080/17512433.2021.1947796 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2021 Oct;14(10):1193-1204. doi: 
      10.1080/17512433.2021.1947796. Epub 2021 Jul 7.